BeiGene (HKSE:06160) Total Stockholders Equity : HK$27,201 Mil (As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is BeiGene Total Stockholders Equity?

BeiGene's Total Stockholders Equity for the quarter that ended in Mar. 2025 was HK$27,201 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. BeiGene's Book Value per Share for the quarter that ended in Mar. 2025 was HK$19.38. The ratio of a company's debt over equity can be used to measure how leveraged this company is. BeiGene's Debt-to-Equity for the quarter that ended in Mar. 2025 was 0.28.

BeiGene Total Stockholders Equity Historical Data

The historical data trend for BeiGene's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Total Stockholders Equity Chart

BeiGene Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

29,993.99

47,827.86

34,126.17

27,625.82

25,902.69

BeiGene Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Stockholders Equity	Get a 7-Day Free Trial															26,288.10	26,290.45	26,770.45	25,902.69	27,201.02

BeiGene (HKSE:06160) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

BeiGene's Book Value per Share for the quarter that ended in Mar. 2025 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(27201.015	-	0)	/	1403.282
	=	19.38

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

BeiGene's Debt-to-Equity for the quarter that ended in Mar. 2025 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(6076.565	+	1671.556)	/	27201.015
	=	0.28

BeiGene Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of BeiGene's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

BeiGene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (HKSE:06160) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

BEIGF:USA ONC:USA 49B:Germany 688235:China B1ME34:Brazil

Address

c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108

Website

https://www.beigene.com

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

Executives

Jpmorgan Chase & Co.	2502 Approved lending agent
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Oyler John Victor	2101 Beneficial owner
Hhlr Advisors, Ltd.	2102 Investment manager
Hhlr Fund, L.p.	2101 Beneficial owner
Baker Brothers Life Sciences Capital, L.p.	2201 Interest of corporation controlled by you
Baker Felix James	2201 Interest of corporation controlled by you
Baker Julian Charles	2201 Interest of corporation controlled by you
Baker Bros. Advisors (gp) Llc	2201 Interest of corporation controlled by you
Amgen Inc.	2101 Beneficial owner
Hillhouse Capital Advisors, Ltd.	2102 Investment manager
Gaoling Fund, L.p.	2101 Beneficial owner
Fidelity Management & Research Company
Fmr Co., Inc.

BeiGene Headlines

No Headlines